Literature DB >> 1642937

Pharmacokinetics of propofol during and after long-term continuous infusion for maintenance of sedation in ICU patients.

G R Bailie1, I D Cockshott, E J Douglas, B J Bowles.   

Abstract

The pharmacokinetics of propofol administered as long term infusions were determined in 12 intensive care unit patients (two female; mean age 58 yr, mean weight 66.9 kg) requiring sedation during mechanical ventilation. Patients were recruited after having been administered propofol for 24 h. Blood samples for analysis of propofol were taken during the infusion (mean duration 85.6 h; mean rate 2.58 mg kg-1 h-1) and for up to about 42 h after its termination. The median propofol total body clearance, derived from the apparent steady state propofol blood concentrations during infusion, was 2.11 litre min-1. One patient died during the infusion, from multi-organ failure secondary to a pre-existing septicaemia, and in one other patient no sampling was possible during the first 30 min after infusion; full elimination data were obtained for 10 patients. After termination of the infusion, propofol blood concentrations declined rapidly, with an overall mean decrease of 50% over the first 10 min; thereafter the decline was more gradual. The elimination profile was triphasic in seven patients and biphasic in three patients. Mean half-lives for the three phases were 1.81 (n = 10) min, 70.9 (n = 7) min and 1411 (n = 11) min. There was no apparent trend in the terminal phase half-life with the duration of sampling after infusion.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1642937     DOI: 10.1093/bja/68.5.486

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  18 in total

1.  Use of propofol to control refractory involuntary movements.

Authors:  David V Lardizabal; Vivek Sabharwal; Ali Jahan; Samay Jain; Christopher Snyder; Marc J Popovich; Michael DeGeorgia
Journal:  Neurocrit Care       Date:  2004       Impact factor: 3.210

Review 2.  Pain relief following cardiac surgery: a review.

Authors:  A Taylor; D Phelan; J R McCarthy
Journal:  Ir J Med Sci       Date:  1996 Jan-Mar       Impact factor: 1.568

Review 3.  [Brain death diagnosis after sedation with propofol or sufentanil. Recommendations for the usage of toxicological analytics].

Authors:  U Walter; U Brüderlein; M Gloger; S Mann; U Walther
Journal:  Med Klin Intensivmed Notfmed       Date:  2014-09-26       Impact factor: 0.840

4.  Acute gonadotroph and somatotroph hormonal suppression after traumatic brain injury.

Authors:  Justin Wagner; Joshua R Dusick; David L McArthur; Pejman Cohan; Christina Wang; Ronald Swerdloff; W John Boscardin; Daniel F Kelly
Journal:  J Neurotrauma       Date:  2010-06       Impact factor: 5.269

5.  Assessing circadian rhythms in propofol PK and PD during prolonged infusion in ICU patients.

Authors:  Agnieszka Bienert; Krzysztof Kusza; Katarzyna Wawrzyniak; Edmund Grześkowiak; Zenon J Kokot; Jan Matysiak; Tomasz Grabowski; Anna Wolc; Paweł Wiczling; Miłosz Regulski
Journal:  J Pharmacokinet Pharmacodyn       Date:  2010-06-11       Impact factor: 2.745

Review 6.  Pharmacokinetics of drugs used in critically ill adults.

Authors:  B M Power; A M Forbes; P V van Heerden; K F Ilett
Journal:  Clin Pharmacokinet       Date:  1998-01       Impact factor: 6.447

Review 7.  Propofol: a review of its use in intensive care sedation of adults.

Authors:  Kate McKeage; Caroline M Perry
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

Review 8.  Pharmacokinetics and pharmacodynamics of sedatives and analgesics in the treatment of agitated critically ill patients.

Authors:  B K Wagner; D A O'Hara
Journal:  Clin Pharmacokinet       Date:  1997-12       Impact factor: 6.447

Review 9.  Propofol in patients with cardiac disease.

Authors:  N R Searle; P Sahab
Journal:  Can J Anaesth       Date:  1993-08       Impact factor: 5.063

Review 10.  Propofol. An overview of its pharmacology and a review of its clinical efficacy in intensive care sedation.

Authors:  B Fulton; E M Sorkin
Journal:  Drugs       Date:  1995-10       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.